Allarity Therapeutics will present a Trial-in-Progress poster on its Phase 2 stenoparib study for platinum-resistant ovarian cancer at the ESMO Gynaecological Cancers Congress in Copenhagen. The presentation showcases the clinical rationale for the dual PARP and WNT pathway inhibitor ahead of upcoming clinical milestones.